花旗发表研究报告指，信达生物旗下IBI363(PD-1/IL-2alpha-bias双特异性抗体融合蛋白产品)，获意见领袖们突显出良好的数据，及有潜力成为下一代免疫肿瘤治疗(IO)关键产品。花旗认为，信达生物可能带来更广范围、高效、低毒的创新癌症治疗，而信达生物维持其2027年实现200亿元产品收入的目标，并于2030年推进五项管线资产进入国际多中心临床实验(MRCT)第三期。 花旗认为，信达生物已进入新阶段，受强劲商业表现及全球创新驱动，并基于折现现金流(DCF)方法，将其目标价从60港元上调至90港元，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.